ATR Q4 2025 Earnings Call Summary

Summary of Aptar's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

Q4 2025 Performance:
- Reported sales: $963 million (up 14% YoY from $848 million).
- Core sales: Increased by 5%.
- Adjusted EBITDA: $191 million (down 2% YoY), with an adjusted EBITDA margin of 19.8% (down from 23% YoY).
- Adjusted earnings per share (EPS): $1.25 (down 23% YoY from $1.62).
Full Year 2025 Performance:
- Reported sales: $3.8 billion (up 5% YoY).
- Core sales: Increased by 2%.
- Reported net income: $393 million (up 5% YoY).
- Adjusted EPS: $5.74 (down 1% YoY).
- Free cash flow: $303 million, down $64 million YoY due to timing of tax payments and higher pension contributions.

2. Strategic Updates and Business Highlights

Segment Performance:
- Pharma: Core sales increased by 4%, driven by strong demand for elastomeric components and systemic nasal drug delivery technologies. Excluding emergency medicine, core sales grew 10%.
- Beauty: Core sales increased by 10%, with operational disruptions noted but expected to improve in 2026.
- Closures: Core sales rose by 1%, with solid growth in beverages but impacted by lower resin pricing.
Innovation and Pipeline:
- Significant advancements in the Pharma pipeline, including FDA approval for CARDAMYST, a self-administered nasal spray for PSVT.
- Continued focus on sustainability, recognized by CDP Climate A list and Newsweek's ranking of America's most responsible companies.

3. Forward Guidance and Outlook

Q1 2026 Guidance: Adjusted EPS expected to be between $1.13 and $1.21.
Full Year 2026 Outlook: Anticipates continued strong growth in Pharma (excluding emergency medicine) and improvements in Beauty and Closures. However, expects a revenue headwind of approximately $65 million from emergency medicine, particularly impacting the first half of the year.
Capital investments projected between $260 million and $280 million for 2026, with a focus on productivity improvements.

4. Bad News, Challenges, or Points of Concern

Margin Declines: Adjusted EBITDA margins decreased due to unfavorable product mix and higher production costs, particularly in Beauty and Closures.
Emergency Medicine Decline: Anticipated continued headwinds in 2026, with a significant impact on overall margins and revenue.
Operational Disruptions: Notable issues in Beauty and Closures segments due to environmental compliance upgrades and supplier challenges, which are expected to improve but have affected margins.

5. Notable Q&A Insights

Pharma Growth: Management expects high single-digit to low double-digit growth in injectables, with GLP-1s contributing but not being the sole driver.
Margin Recovery: Q1 margins are expected to improve sequentially, with significant recovery anticipated in the second half of 2026.
NARCAN Business: Management clarified that they did not lose the NARCAN business but faced destocking challenges. Long-term growth is expected to stabilize at low to mid-single digits.
Capital Allocation: The $600 million share repurchase authorization reflects a commitment to returning capital to shareholders while maintaining flexibility for growth investments.

Overall, Aptar's Q4 2025 results reflect strong top-line growth amid operational challenges, with a cautious outlook for 2026 driven by expected headwinds in emergency medicine and ongoing efforts to improve margins across segments.

ATR — AptarGroup, Inc.